Zydus

Zydus is the brand associated with Zydus Lifesciences Limited and the wider Zydus Group, an Indian pharmaceutical and healthcare business headquartered in Ahmedabad, Gujarat. The company traces its origins to 1952, when it was founded by Ramanbhai B. Patel. The official company account describes Zydus Lifesciences as the former Cadila Healthcare Limited and presents it as a fully integrated global healthcare provider with capabilities across the pharmaceutical value chain. Its business spans pharmaceutical formulations, active pharmaceutical ingredients, animal healthcare and wellness products. The company describes its work as focused on pharmaceutical and healthcare innovation and on addressing unmet healthcare needs. Its product portfolio includes medicines across therapeutic categories such as cardiovascular care, gastrointestinal conditions, anti-infectives, pain management and antimalarials. The company also highlights Oxemia (desidustat), an oral prescription treatment for anemia associated with chronic kidney disease in India; the site notes that it should be used under the advice and guidance of a nephrologist or internal medicine specialist. Zydus serves India and international markets. Its official homepage describes a presence in regulated markets including the United States and Europe, naming France and Spain, as well as high-profile markets in Latin America. The group reports manufacturing sites and research facilities across five Indian states—Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim—and in the United States and Brazil. The homepage states that the group has more than 30,000 people and ranks fourth in the Indian pharmaceutical industry. The Zydus Group was restructured in 1995, when Cadila Healthcare was formed under its aegis. The company has since operated as a broad-based healthcare provider rather than a single-product label. Its stated brand promise is “dedicated to life in all its dimensions,” alongside a mission to create healthier, happier communities across the globe. The company page reports turnover of over Rs. 23,200 crores in FY25; this is presented as a company-reported figure, not an independently verified financial conclusion. The supplied material does not identify a controlling owner or specific listed securities.

Zydus traces its origins to 1952, when Ramanbhai B. Patel founded the company that developed into the present-day Zydus business. The supplied company history presents this beginning as the start of a pharmaceutical lineage that later grew into a broader healthcare group. It describes Patel as a first-generation entrepreneur and a prominent figure in Indian pharmaceuticals. A key organizational turning point came in 1995. According to the company, the group was restructured and Cadila Healthcare was formed under the aegis of the Zydus Group. This established the corporate structure through which the business developed its pharmaceutical and healthcare operations. The company’s current identity is Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited. Over time, Zydus built capabilities across multiple parts of the pharmaceutical value chain. Its stated business areas include formulations, active pharmaceutical ingredients, animal healthcare products and wellness products. The company describes itself as a fully integrated global healthcare provider, combining this range of products with research, manufacturing and international business activities. The official homepage reports manufacturing sites and research facilities in Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India, as well as in the United States and Brazil. The company’s markets extend beyond India. Its official site identifies the United States and Europe—including France and Spain—as regulated markets in which its global business has a presence, and also describes activity in Latin America. The group has presented innovation and addressing unmet healthcare needs as continuing priorities. The homepage has featured Oxemia (desidustat), an oral treatment for anemia associated with chronic kidney disease in India, while cautioning that it is a prescription medicine to be used under specialist advice. Zydus describes its brand promise as being dedicated to life in all its dimensions and its mission as creating healthier, happier communities across the globe. The company page reports turnover of over Rs. 23,200 crores in FY25. The homepage also states that the group has over 30,000 people and ranks fourth in the Indian pharmaceutical industry. These are company-reported descriptions and figures. The supplied material does not provide a detailed account of later acquisitions, leadership changes, listing particulars or a comprehensive chronology, so those events are not added here.

• 2025

  Company reports FY25 turnover

• 1995

  Group restructuring and formation of Cadila Healthcare

• 1952

  Company founded by Ramanbhai B. Patel

• Identity as Zydus Lifesciences Limited

An innovation-oriented, integrated global pharmaceutical and healthcare provider focused on comprehensive healthcare solutions and unmet medical needs.

• Oxemia (desidustat)

  An oral prescription treatment highlighted by the company for anemia associated with chronic kidney disease in India. The company advises use under the guidance of a nephrologist or internal medicine specialist.

• Aten

  A cardiac product line listed in the company's India formulations catalogue.

• Falcigo

  An antimalarial product line listed in the company's India formulations catalogue.

• Nucoxia

  A pain and analgesics product line listed in the company's India formulations catalogue.

• Ocid

  A gastrointestinal product line listed in the company's India formulations catalogue.

• Linid

  An anti-infective product line listed in the company's India formulations catalogue.

• Oxalgin

  A pain-management product line listed in the company's India formulations catalogue.

• 1995

  1995 group restructuringOther

1. 1Leading Global Pharmaceutical Company in India - Zydus group - Zyduszyduslife.com
2. 2About Zydus Group - The Leading Indian Pharma Companyzyduslife.com
3. 3Zydus Group Products - Pharmaceuticals, Wellness & Healthcarezyduslife.com
4. 4Leading Global Pharmaceutical Company in India - Zydus group - Zyduszyduslife.com
5. 5Medicure acquires full US ownership of Zypitamagbiospectrumindia.com
6. 6Medicure Announces Acquisition Of Full United States Ownership Of Zypitamag™prnewswire.com
7. 7Zydus launches Remdac™ (Remdesivir) for the treatment of COVID 19 in Indiaequitybulls.com
8. 8Zydus slashes COVID 19 drug Remdesivir price by over two third; now costs Rs 899 - BusinessTodaybusinesstoday.in